Lupin Launches Methergine In US

The Economic Times - - Companies: Pursuit Of Profit -

Drug maker Lupin is bol­ster­ing its US branded drugs port­fo­lio with the in­tro­duc­tion of Methergine, an oral tablet used to treat post­par­tum haem­or­rhage, in the US mar­ket, Our Bureau. The Mum­bai-based com­pany said it has put sig­nif­i­cant in­vest­ment in pro­fes­sional ed­u­ca­tion in pro­mot­ing the drug, which it hoped can be used to han­dle the ris­ing in­ci­dences of ma­ter­nal deaths that are caused by ex­ces­sive bleed­ing.

Lupin’s lat­est launch and in­vest­ments in the prod­uct points to a grow­ing trend of In­dian com­pa­nies to seek rev­enues from branded drugs. The US is Lupin’s largest mar­ket and con­trib­uted 45% to the com­pany’s $2.06 bil­lion rev­enue in FY2015.

Lupin ven­tured into branded spe­cialty prod­ucts with its an­tibi­otic Suprax.

MUM­BAI

Newspapers in English

Newspapers from India

© PressReader. All rights reserved.